Last ¥2,188 JPY
Change Today -4.00 / -0.18%
Volume 902.1K
4507 On Other Exchanges
As of 2:00 AM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

shionogi & co ltd (4507) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/22/13 - ¥2,390
52 Week Low
04/11/14 - ¥1,733
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SHIONOGI & CO LTD (4507)

Related News

No related news articles were found.

shionogi & co ltd (4507) Related Businessweek News

No Related Businessweek News Found

shionogi & co ltd (4507) Details

Shionogi & Co., Ltd. manufactures and distributes pharmaceuticals, diagnostic reagents, and medical devices primarily in Asia, North America, and Europe. Its principal products include various prescription drugs, including Crestor tablets for the treatment of hyperlipidemia; Irbetan tablets, an antihypertensive; Cymbalta capsules to treat depression, depressive condition, and diabetic neuropathic pain; cancer pain analgesics, such as OxyContin tablets, OxiNorm powders, and OxiFast injections; Finibax and Finibax solution kit for intravenous drip infusion; Differin gel for the treatment of topical acne vulgaris; Pirespa tablets used to treat idiopathic pulmonary fibrosis; and Rapiacta, an antiviral drug for the treatment of influenza. The company also offers over the counter drugs comprising Popon-S Plus, a multiple vitamin and mineral; and Sedes, a line of analgesic antipyretics. In addition, it provides diagnostics reagents, such as MI02 Shionogi BNP and Shionospot BNP, a human brain natriuretic peptide kit; Allerport TARC, a thymus and activation-regulated chemokine kit; Brightpoc Flu, an influenza virus diagnostic kit; and Checkart, a testing system for standard diabetes diagnosis market. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

6,165 Employees
Last Reported Date: 06/25/14
Founded in 1878

shionogi & co ltd (4507) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

shionogi & co ltd (4507) Key Developments

Shionogi & Co., Ltd. Presents at 2014 Russian Pharmaceutical Forum, Jun-17-2014 05:45 PM

Shionogi & Co., Ltd. Presents at 2014 Russian Pharmaceutical Forum, Jun-17-2014 05:45 PM. Venue: Corinthia Saint-Petersburu Hotel, 57 Nevskij Prospect, St. Petersburg, Russia. Speakers: Toshiya Nakagawa, General Manager and Head of Global Sales Overseas Business Division.

Shionogi Establishes New ASEAN Headquarters in Singapore

Shionogi has announced that it has established a wholly-owned Association of Southeast Asian Nations (ASEAN) headquarters in Singapore. The new headquarters, dubbed Shionogi Singapore, will be used by the company to maximize the value of Shionogi's products in the member states of ASEAN by acting as a development and sales foothold in the region. The establishment of the new ASEAN headquarters fits in with Shionogi's new Medium-Term Business Plan, started in April this year, by which the company is focusing its operating resources on the Japanese and US pharmaceutical markets as important growth areas, and also considering Asian countries as important markets for the future launch of new drugs. The new focus is aimed at minimizing the impact of the expiry of the patent for Shionogi's hyperlipidaemia drug Crestor (rosuvastatin) from 2016.

Shionogi Reports Earnings Results in the Twelve Months Ended to March 31, 2014; Provides Earnings Guidance for the Year 2014

Shionogi reported earnings results in the twelve months ended to March 31, 2014. The company has announced that its sales increased by 2.4% to reach JPY 289.7 billion (USD 2.84 billion) in the twelve months to March 31, 2014. Meanwhile, the company's operating profits were up by as much as 6.7% to JPY 63.6 billion, although net profits slumped by 37.3% to JPY 41.8 billion. The company is forecasting that its net sales will decline by 7.2% to JPY 269.0 billion, partly because of the April 2014 National Health Insurance (NHI) drug price revisions in Japan and partly because of the reduced royalties from Crestor. Meanwhile, the company expects operating income to decline by 29.2% to JPY 50.0 billion and net income to fall by 21.1% to JPY 33.0 billion.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4507:JP ¥2,188.00 JPY -4.00

4507 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $42.91 USD -0.185
Cubist Pharmaceuticals Inc $63.28 USD -2.42
Pfizer Inc $30.48 USD -0.01
Shire PLC 4,977 GBp +22.00
Theravance Inc $25.47 USD -2.21
View Industry Companies

Industry Analysis


Industry Average

Valuation 4507 Industry Range
Price/Earnings 17.9x
Price/Sales 2.6x
Price/Book 1.6x
Price/Cash Flow 18.7x
TEV/Sales 2.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIONOGI & CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at